|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Sagent Pharmaceuticals, Inc. Announces Launch of Irinotecan Hydrochloride Injection in Single Dose Vials
5/17/2012 9:49:05 AM
SCHAUMBURG, Ill., May 17, 2012 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Irinotecan Injection, the generic form of the chemotherapy drug Camptosar®, in two latex free, preservative free single dose vials. According to IMS data for the twelve-months ended March 2012, the U.S. market for Irinotecan approximated $28 million. As with all products in Sagent's portfolio, Irinotecan features the company's PreventIV MeasuresSM packaging and labeling designed to aid in the reduction of medication errors.
|
|
|
|
|
|
|
|
|
|
|